Due to the restricted publication terms in the Material Transfer Agreement of these studies, data included in this meta-analysis are only available upon request. Requests for access to study data from Step, Phambili, HVTN 505 and HVTN 204 should be sent to the HVTN: <vtn.research@hvtn.org> or by completion of a form on the HVTN website: <http://www.hvtn.org/en/science/submit-idea-proposal/idea-submission.html>. Requests for access to RV 172 data should be sent to Dr. Merlin Robb (<mrobb@hivresearch.org>) at USMHRP. Requests for access to IAVI V001 data should be sent to Dr. Frances Priddy (<FPriddy@iavi.org>) at IAVI. Once approved, data will be provided via secure data transfer protocols.

Introduction {#sec005}
============

Credited to their immunological and manufacturing properties, replication-defective adenovirus (Ad) vectors have been one of the most explored delivery vehicles of vaccines for cancer and a variety of pathogens, including HIV-1, *Plasmodium falciparum*, *Mycobacterium tuberculosis*, hepatitis C, Ebola and Influenza (reviewed in \[[@pone.0136626.ref001]\]). In preventive HIV-1 vaccine development, three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have been conducted to evaluate regimens containing recombinant Ad serotype 5 (rAd5) vector vaccines expressing HIV-1 antigens. The first two studies, Step \[[@pone.0136626.ref002]\] and Phambili \[[@pone.0136626.ref003]\], tested the MRKAd5 HIV-1 *gag/pol/nef* vaccine. Vaccinations in Step were stopped early due to efficacy futility observed at the first interim analysis, which caused the discontinuation of enrollment and vaccinations in Phambili. The third study, HVTN 505 (HVTN505) \[[@pone.0136626.ref004]\], tested a DNA prime- rAd5 HIV-1 *env/gag/pol* boost vaccine. Vaccinations in HVTN505 were also stopped early due to efficacy futility observed at the first interim analysis. Shortly after stopping of the vaccinations, participants of these studies were unblinded to their vaccination assignments but continued follow--up ([Fig 1](#pone.0136626.g001){ref-type="fig"}). Before the efficacy trials, three Phase 1--2 Triad studies, IAVI V001 (IAVI001) \[[@pone.0136626.ref005]\], RV 172 (RV172) \[[@pone.0136626.ref006]\] and HVTN 204 (HVTN204) \[[@pone.0136626.ref007]\], tested the same HVTN505 DNA/rAd5 vaccine regimen.

![Enrollment and Follow-up in Step, Phambili and HVTN505.\
Indicated are dates of unblinding when data were frozen for pre-unblinding analyses, and the percent of person-years (% pyrs) occurring during the blinded period. HVTN505 is still in active follow-up; HVTN505 data included in the meta-analysis are as of July 9, 2014.](pone.0136626.g001){#pone.0136626.g001}

Post-hoc analysis of Step data revealed trends toward an increased risk of HIV-1 acquisition among vaccine recipients that waned over time, especially among males who had positive anti-Ad5 neutralizing antibodies (Ad5-positive) or were uncircumcised at baseline \[[@pone.0136626.ref002], [@pone.0136626.ref008]\]. Such a finding was not observed in the analyses of Phambili data shortly following study unblinding \[[@pone.0136626.ref003]\], nor of the long-term follow-up data \[[@pone.0136626.ref009]\].To clearly understand whether vaccine-associated increase of HIV-1 acquisition has occurred in one or more studies, we conducted a meta-analysis using up-to-date participant-level data from the efficacy trials and the three Triad studies. The objectives were to evaluate: 1) the effect of rAd5 vector vaccines on HIV-1 acquisition, and 2) variation in the effect across vaccine regimens, time since vaccination, and subgroups.

By combining information from multiple studies of similar interventions, a meta-analysis can provide clearer signals overall and in subgroups. However, this strength is predicated on the assumption that it is meaningful to combine data from multiple studies conducted in different populations with different Ad5 vector characteristics, expressing different HIV-1 antigens, and employing different vaccine regimens. In this individual participant data (IPD) meta-analysis, we obtained the raw individual level data from each study before they were combined for analyses, which is commonly referred to as individual patient data (IPD) meta-analysis when diseased study populations are involved. Compared to meta-analysis based on aggregated study-level summary data, IPD-based meta-analyses is usually more time-consuming but possesses many advantages, including but not limited to: 1) the statistical analysis can be standardized across studies; 2) complex relationships such as time-dependent effects can be modeled; 3) prognostic models (e.g., risk scores) can be generated and validated, and multiple individual level factors can be examined in combination; 4) estimates adjusted for baseline (prognostic) factors can be produced, which may increase statistical power and allow adjustment for potential confounding factors; and 5) meta-analysis results for specific subgroups of participants can be obtained across studies, and differential (treatment) effects can be assessed across individuals, which can help reduce between-study heterogeneity (e.g., \[[@pone.0136626.ref010], [@pone.0136626.ref011]\]).

Methods {#sec006}
=======

Study selection and data extraction {#sec007}
-----------------------------------

Fred Hutchinson Cancer Research Center Institutional Review Board approved the described study. Consultation with HIV-1 vaccine developers and vaccine research experts, as well as a systematic literature search through February 2015 of the US National Library of Medicine ([PubMed.gov](http://PubMed.gov)), Ovid Medline (R) (1946-present) and [clinicaltrials.gov](http://clinicaltrials.gov/) was conducted to identify all randomized trials of Ad5-vectored preventive HIV-1 vaccines (Methods in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). Participant-level data were directly provided by the coordinating centers of the selected studies. A completed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist is provided in [S2 Supporting Information](#pone.0136626.s002){ref-type="supplementary-material"}.

Individual-study features {#sec008}
-------------------------

The three Phase 2b trials enrolled participants at increased risk for HIV-1 infection in the Americas and Australia (Step), South Africa (Phambili) and the US (HVTN505); the three Phase 1--2 trials enrolled participants at low to intermediate risk for HIV-1 infection in East Africa (IAVI001 and RV172), and in the Americas and South Africa (HVTN204). With the exception of HVTN505, which enrolled circumcised men who have sex with men (MSM) and transgender women with no pre-existing anti-Ad5 antibodies (Ad5-negative), the studies enrolled men and non-pregnant women with no specific eligibility criteria based on baseline Ad5 serostatus or circumcision status ([Table 1](#pone.0136626.t001){ref-type="table"}). Step and Phambili evaluated the MRKAd5 HIV-1 vaccine administered at weeks 0, 4 and 26 \[[@pone.0136626.ref002], [@pone.0136626.ref003]\]. HVTN505 and the Triad studies evaluated the 6-plasmid VRC-DNA vaccine administered at weeks 0, 4, and 8, followed by the VRC-rAd5 boost administered at week 24 \[[@pone.0136626.ref004]\]. The DNA placebo was phosphate-buffered saline and the rAd5-HIV placebo was vaccine diluent only \[[@pone.0136626.ref002]--[@pone.0136626.ref004]\]. The Phase 1--2 trials evaluated the same vaccines as HVTN505. Each individual protocol was approved by institutional review boards at all participating sites. All study participants provided written informed consent.

10.1371/journal.pone.0136626.t001

###### Key Features of Individual Studies Included in the Meta-analysis.
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                                            Step \[[@pone.0136626.ref002]\]                                                                                                                                                                                                                                      Phambili \[[@pone.0136626.ref003], [@pone.0136626.ref009]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        HVTN505 \[[@pone.0136626.ref004]\]                                                                        IAVI001 \[[@pone.0136626.ref005]\]                      RV172 \[[@pone.0136626.ref006]\]                                                           HVTN204 \[[@pone.0136626.ref007]\]
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------
  **Vaccine regimen**                       rAd5 (week 0), rAd5 (Week 4), rAd5 (week 26)                                                                                                                                                                                                                         DNA (Week 0), DNA (Week 4), DNA (Week 8), rAd5 (Week 24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Vaccine products**                      The MRKAd5 HIV-1 gag/pol/nef vaccine consists of a 1:1:1 mixture of three separate replication-defective Ad5 vectors, one each expressing the gag gene from the HIV-1 strain CAM-1, the pol gene from HIV-1 strain IIIB, and the nef gene from HIV-1 strain JR-FL.   The DNA-HIV vaccine (VRC-HIVDNA-016-00-VP) consists of six DNA plasmid in equal concentrations that encode Gag from the clade B HIV-1 strain HXB2, Pol from the clade B HIV-1 strain NL4-3, and Nef from the clade B strain NY5/BRU, and HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strain HXB2/BaL), and clade C (strain 97ZA012). The rAd5-HIV vaccine (VRC-HIVADV014-00-VP) consists of four rAd5 vectors in 3:1:1 ratio that encode the HIV-1 Gag-Pol polyprotein from clade B (strains HXB2-NL4-3) and HIV-1 Env glycoproteins from clades A, B and C matching the DNA Env components.                                                                                                                                                                                                                                                                
  **Vaccine dose**                          1.5x10\^10 viral genomes of MRKAd5                                                                                                                                                                                                                                   Four mg of VRC-DNA; 10\^10 particle unit of VRC-Ad5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Four mg of VRC-DNA, 10\^10 or 10\^11 particle unit of VRC-Ad5                                             Same as HVTN505                                                                                                                                    
  **Placebo product**                       Vaccine diluent with no Ad5 vector                                                                                                                                                                                                                                   Sterile phosphate buffered saline as DNA placebo; vaccine diluent with no Ad5 vector as Ad5 placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  **Delivery method**                       Intramuscular injection of Ad5/placebo using a needle and syringe                                                                                                                                                                                                    Intramuscular injection of DNA/placebo using Bioinjector 2000 Needle-Free Injection System; intramuscular injection of Ad5/placebo using a needle and syringe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **Study population**                      High-risk, HIV-1 uninfected men who have sex with men and heterosexual men and non-pregnant women aged 18--50 years                                                                                                                                                  High-risk predominantly heterosexual men and non-pregnant women aged 18--35 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  High-risk circumcised and Ad5-negative men or transgender women who have sex with men aged 18--50 years   Low risk men and non-pregnant women aged 18--50 years   Low or intermediate risk men and up-pregnant women aged 18--50 years                       Low or intermediate risk men and non-pregnant women aged 18--50 years
  **Study regions**                         North America, the Caribbean, South America, and Australia                                                                                                                                                                                                           South Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       United States                                                                                             East Africa (Kenya, Rwanda)                             East Africa (Uganda, Kenya, Tanzania)                                                      The Americas (United States, Haiti, Jamaica and Brazil) and South Africa
  **Randomization scheme**                  1:1 (vaccine: placebo) randomization ratio pre-stratified by study site, sex, and baseline Ad5 antibody titer                                                                                                                                                        1:1 (vaccine: placebo) randomization ratio pre-stratified by study site and sex                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1:1 (vaccine: placebo) randomization ratio pre-stratified by study site                                   3:1 (vaccine: placebo) randomization ratio              1:1 (vaccine: placebo) randomization ratio for 180 participants; 2:1 ratio for the rest.   1:1 (vaccine: placebo) randomization ratio pre-stratified by geographical region
  **Study enrollment period**               2004--2007                                                                                                                                                                                                                                                           2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               2009--2013                                                                                                2005--2006                                              2006                                                                                       2006--2007
  **Number of total randomized subjects**   3000                                                                                                                                                                                                                                                                 801                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2530                                                                                                      79                                                      281                                                                                        466
      Vaccine                               1494                                                                                                                                                                                                                                                                 400                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1264                                                                                                      58                                                      158                                                                                        233
      Placebo                               1506                                                                                                                                                                                                                                                                 401                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1266                                                                                                      21                                                      123                                                                                        233
  **Number of MITT subjects**               2970                                                                                                                                                                                                                                                                 800                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2496                                                                                                      79                                                      281                                                                                        466
      Vaccine                               1478                                                                                                                                                                                                                                                                 400                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1251                                                                                                      58                                                      158                                                                                        233
      Placebo                               1492                                                                                                                                                                                                                                                                 400                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1245                                                                                                      21                                                      123                                                                                        233

Meta-analysis endpoint and cohorts {#sec009}
----------------------------------

The study endpoint was HIV-1 infection diagnosed during study follow-up. We predefined two co-primary analysis cohorts for assessing the vaccine effect on HIV-1 acquisition. The modified-intention-to-treat (MITT) cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received at least the first vaccine/placebo, and the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Post-randomization selection bias could possibly exist in the Ad5 cohort but not in the MITT cohort. The study included follow-up data through July 9, 2014.

Statistical analysis {#sec010}
--------------------

All reported meta-analyses were adjusted for baseline factors that could potentially confound the vaccine effect on HIV-1 infection, especially during the post-unblinding period. The following baseline factors were considered: region (North America + Australia vs. Other), age, sex, HSV-2 serostatus, race (White vs. Other), baseline Ad5 sero-positivity (Ad5-positive vs. Ad5-negative), self-reported circumcision status (circumcised vs. uncircumcised), and behavioral risk score. The behavioral risk score was developed to summarize the level of risk behaviors for men and women. It takes a value from 0 to 7 for men and from 0 to 6 for women. The risk score is defined as the number of high risk behaviors a subject self-reported during the 3--6 months prior to enrollment: for men 1) number of male partners \>2, 2) use of any recreational or injected drug, 3) unprotected insertive anal sex, 4) unprotected receptive anal sex, 5) unprotected vaginal sex, 6) exchange sex for money, goods or services, 7) other sexually transmitted infections (STIs); and for women: 1) number of male partners \>2, 2) use of any recreational or injected drug, 3) unprotected anal sex, 4) unprotected vaginal sex, 5) exchange sex, and 6) other STIs.

We measured the vaccine effect as one minus the hazard ratio (HR) of infection (vaccine: placebo) using multivariable Cox regression models stratified by study. To reduce bias due to inclusion of post-unblinding data, the Cox models adjusted for the aforementioned potential baseline confounding variables that best predicted infection based on all-subsets model selection and the exact Akaike's information criterion (AIC). Grambsch and Therneau's test \[[@pone.0136626.ref012]\] was applied to assess whether the adjusted HR was constant over time. For the co-primary analyses, the time-to-event variable was defined as the time from enrollment/initial vaccination (MITT cohort) or the first rAd5-HIV vaccination (Ad5 cohort) to the estimated time of HIV-1 infection. The estimated infection time, for the Phase 2b studies, was the midpoint between the last HIV-1 seronegative visit date and the first evidence of HIV-1 infection date based on both HIV-1 antibody and nucleic acid blood testing, and for the Phase 1--2 studies, was the date of HIV-1 diagnosis confirmed by ELISA, Western blot and RT-PCR. Participants who never showed any evidence of HIV-1 infection were right censored on the date of last HIV-1 test. For secondary analyses that restricted to data before unblinding or in the first 18 months following vaccination, we censored the follow-up time at the date of study unblinding or 18 months. We generated group-specific Kaplan-Meier (KM) curves, group difference of the cumulative probability of HIV-1 infection, and estimated non-parametric instantaneous HRs over time with 95% simultaneous confidence intervals \[[@pone.0136626.ref013]\].

We used Wald interaction tests based on Cox models to assess whether the vaccine effect differed by study, vaccine regimen, baseline covariates (sex, Ad5 serostatus, circumcision status), and time-varying covariates: time-period (follow-up time (FU) before or after 18 months since enrollment, i.e., FU≤18 months or FU\>18 months) and number of rAd5-HIV vaccinations received (1, 2 or 3). Before looking into differences within a specific subset of studies or examining the effects of a specific vaccine regimen, we first conducted overall interaction tests to assess whether the vaccine effect differed across all six studies or all three efficacy trials, followed by interaction tests to assess whether the vaccine effect differed between the two vaccine regimens. Holm-Bonferroni family-wise-error-rate (FWER)-adjusted p-values and false-discovery-rate (FDR)-adjusted q-values were calculated to reflect the potential effect of multiple testing on type I errors. All reported p values were two-sided.

To investigate the power of this study in examining whether the two vaccine regimens were similar in terms of their effect on HIV-1 infection as compared to placebo recipient, we calculated the power for comparing different true HRs between Step+Phambili and HVTN505. The purpose of such power calculations was not to justify statistically non-significant results in a single study, but rather to provide an understanding of the capability of the meta-analysis in assessing whether several experiments (i.e., Step+Phambili vs. HVTN505) were similar \[[@pone.0136626.ref014]\]. The power calculations were based on the MITT cohort. Briefly, we fixed the total sample size, proportion of subjects randomly allocated to vaccine and placebo, and the number of HIV-1 infections in the placebo groups of HVTN505 and Step+Phambili. Specifically, for HVTN505, we fixed the sample size of 2496, with 1251 and 1245 MITT participants in the vaccine and placebo groups, respectively; we also fixed the number of HIV-1 infections in the placebo group to be 61. For Step+Phambili, we fixed the overall sample size of3770, with 1878 and 1892 MITT participants in the vaccine and placebo groups, respectively; we also fixed the number of HIV-1 infections in the placebo group to be 118. We studied a range of true HRs based on the 95% CI of the estimated HRs from Step+Phambili and HVTN505. Specifically, we chose the true HR of Step+Phambili to vary between 1.11 and 1.78, and the true HR for HVTN505 to vary between 0.47 and 1.26. For each pair of assumed true HRs, we computed the power for testing the equality in HRs between Step+Phambi and HVTN505 based on a Wald test statistic, assuming asymptotic normality of the difference in estimated log(HR) between the two groups; variance of the estimated log(HR) was computed using formula (10) in \[[@pone.0136626.ref015]\]. A 0.05-alpha level was used in the power calculations.

Because potential post-unblinding bias in the analysis could occur due to differential dropout, HIV-1 risk behavior or ascertainment of HIV-1 infection between vaccine and placebo recipients, pre-specified simulation-based sensitivity analyses were used to assess the impact of early unblinding in Step and Phambili. Simulations were also conducted to assess the impact of early stopping in HVTN505 on the reported HR estimates (Methods in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). Statistical analyses were performed with R version 2.15.1 \[[@pone.0136626.ref016]\]. An R function for generating the forest plots presented in this paper is included in the Supplement (Methods in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

Results {#sec011}
=======

We screened 173 articles for eligibility and identified 19 potentially relevant candidate HIV-1 vaccine studies for further review. Among the 19 studies, five evaluated DNA only \[[@pone.0136626.ref017]--[@pone.0136626.ref019]\] or rAd5 only \[[@pone.0136626.ref020], [@pone.0136626.ref021]\] vaccine regimens that are different from the ones evaluated in the efficacy trials; seven \[[@pone.0136626.ref022]--[@pone.0136626.ref028]\] evaluated the same vaccine regimens as the efficacy trials, but there were resource constraints in extracting the individual-level data from those trials. Given only a marginal number of HIV infections would be added to the total HIV infections beyond the three efficacy trials (\< 6%), those 12 studies were excluded from the IPD meta-analysis. After also excluding one duplicate study \[[@pone.0136626.ref002]\], up-to-date participant-level data, some of which have not been previously published, from a total of six randomized, placebo-controlled trials of Ad5-vectored HIV-1 vaccines were included for the final meta-analysis ([Fig 2](#pone.0136626.g002){ref-type="fig"}). [Table 2](#pone.0136626.t002){ref-type="table"} provides key data summary of the six studies. All MITT participants in Step (n = 2970) and Phambili (n = 800) received at least one dose of rAd5-HIV vaccine or rAd5-placebo, whereas 82.8% of MITT participants in HVTN505 (n = 2496), 92.4% in IAVI001 (n = 79), 92.2% in RV172 (n = 281) and 89.1% in HVTN204 (n = 466) received a dose of rAd5-HIV vaccine or rAd5-placebo. The annual loss to follow-up incidence pooled over the vaccine and placebo groups was 10.2% in Step, 8.2% in Phambili and 10.8% in HVTN505. Table A in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"} shows the included information in the meta-analysis as compared to prior publications of the individual trials. Figs A and B in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"} show the covariate-unadjusted cumulative incidences of HIV-1 infection by treatment arm for the individual Phase 2b studies and Triad studies.

![Study Flow Diagram.](pone.0136626.g002){#pone.0136626.g002}

10.1371/journal.pone.0136626.t002

###### Key Data Summary of Individual Studies Included in the Meta-analysis.
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                                                                                                                                       Step\[[@pone.0136626.ref002]\]   Phambili \[[@pone.0136626.ref003], [@pone.0136626.ref009]\]   HVTN505 \[[@pone.0136626.ref004]\]   IAVI001 \[[@pone.0136626.ref005]\]   RV172 \[[@pone.0136626.ref006]\]   HVTN204 \[[@pone.0136626.ref007]\]
  ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------- ------------------------------------------------------------- ------------------------------------ ------------------------------------ ---------------------------------- ------------------------------------
  **Number of MITT subjects**                                                                                                          2970                             800                                                           2496                                 79                                   281                                466
      Vaccine                                                                                                                          1478                             400                                                           1251                                 58                                   158                                233
      Placebo                                                                                                                          1492                             400                                                           1245                                 21                                   123                                233
  **Percent of subjects received**                                                                                                                                                                                                                                                                                                                 
  0 Ad5/Placebo vaccinations                                                                                                           0%                               0%                                                            17.2%                                8%                                   7%                                 10%
  1 Ad5/Placebo vaccinations                                                                                                           3.0%                             27.0%                                                         82.8%                                92.4%                                92.2%                              89.1%
  2 Ad5/Placebo vaccinations                                                                                                           6.8%                             66.1%                                                         Not applicable (NA)                  NA                                   NA                                 NA
  3 Ad5/Placebo vaccinations                                                                                                           90.1%                            6.9%                                                          NA                                   NA                                   NA                                 NA
  **Follow-up time since enrollment (median with range in months)**                                                                    39.1 (0, 51.1)                   42.4 (0, 43.4)                                                25 (0, 58.5)                         67.9 (5.4, 72.3)                     55.3 (1.2, 74.8)                   33.9 (0.4, 37.3)
      Vaccine                                                                                                                          39.2 (0, 50.3)                   42.3 (0, 43.4)                                                25.9 (0, 58.3)                       68.0 (5.4, 72.3)                     56.7 (2, 70.6)                     34.3 (0.4, 37.3)
      Placebo                                                                                                                          39.0 (0, 51.1)                   42.4 (0, 43.4)                                                24.6 (0, 58.5)                       67.9 (48.8,71.8)                     54.2 (1.2, 74.8)                   33.6 (0.9, 37.2)
  **Number of infections: total, FU≤18 months, FU\>18 months**                                                                         187, 93, 94                      100, 51, 49                                                   116, 78, 38                          0, 0, 0                              14, 9, 5                           12, 8, 4
      Vaccine                                                                                                                          106, 55, 51                      63, 29, 34                                                    55, 40, 15                           0, 0, 0                              8, 4, 4                            7, 5, 2
      Placebo                                                                                                                          81, 38, 43                       37, 22, 15                                                    61, 38, 23                           0, 0, 0                              6, 5, 1                            5, 3, 2
  **Number of infections by number of Ad5/placebo vaccinations: total, 0-Ad5/placebo, 1-Ad5/placebo, 2- Ad5/placebo, 3-Ad5/placebo**   187, 0, 1, 23, 163               100, 0, 25, 69, 6                                             116, 19, 97, 0, 0                    0, 0, 0, 0, 0                        14, 1, 13, 0, 0                    12, 7, 5, 0, 0
  Vaccine: total, 0-Ad5, 1-Ad5, 2 Ad5, 3-Ad5                                                                                           106, 0, 0, 10, 96                63, 0, 18, 42, 3                                              55, 10, 45, 0, 0                     0, 0, 0, 0, 0                        8, 1, 7, 0, 0                      7, 4, 3, 0, 0
  Placebo: total, 0-placebo, 1-placebo, 2-placebo, 3-placebo                                                                           81, 0, 1, 13, 67                 37, 0, 7, 27, 3                                               61, 9, 52, 0, 0                      0, 0, 0, 0, 0                        6, 0, 6, 0, 0                      5, 3, 2, 0, 0
  **Annual HIV-1 incidence (%): total, FU≤18 months, FU\>18 months**                                                                   2.2, 2.3, 2.1                    4.4, 4.8, 4.1                                                 2.1, 2.4, 1.8                        0, 0, 0                              1.3, 2.4, 0.7                      1.2, 1.3, 0.9
      Vaccine                                                                                                                          2.5, 2.8, 2.2                    5.6, 5.5, 5.7                                                 2, 2.4, 1.3                          0, 0, 0                              1.3, 1.8, 0.9                      1.3, 1.7, 0.9
      Placebo                                                                                                                          1.9, 1.9, 1.9                    3.2, 4.1, 2.4                                                 2.3, 2.3, 2.2                        0, 0, 0                              1.3, 3.1, 0.3                      1.0, 1.0, 1.0
  **Annual loss to follow-up incidence (%), total, FU≤18 months, FU\>18 months**                                                       10.2, 7.9, 12.2                  8.2, 8.4, 8.1                                                 10.8, 10, 12.2                                                                                               
      Vaccine                                                                                                                          10.0, 7.9, 11.8                  7.8, 8.1, 7.6                                                 9.8, 9.2, 10.6                                                                                               
      Placebo                                                                                                                          10.4, 7.8, 12.7                  8.6, 8.6, 8.6                                                 11.9, 10.7, 13.9                                                                                             
  **Early unblinding date**                                                                                                            10/17/2007                       10/23/2007                                                    4/22/2013                                                                                                    
  **Percent follow-up time at un-blinding**                                                                                            47.3%                            10.9%                                                         67.30%                                                                                                       
      Vaccine                                                                                                                          47.0%                            10.9%                                                         66.80%                                                                                                       
      Placebo                                                                                                                          47.6%                            10.9%                                                         67.90%                                                                                                       
  **Number of infections: total, pre-unblinding, post-unblinding**                                                                     187, 100, 87                     100, 14, 86                                                   116, 88, 28                                                                                                  
      Vaccine                                                                                                                          106, 57, 49                      63, 8, 55                                                     55, 46, 9                                                                                                    
      Placebo                                                                                                                          81, 43, 38                       37, 6, 31                                                     61, 42, 19                                                                                                   
  **Annual HIV-1 incidence (%): total, pre-unblinding, post-unblinding**                                                               2.2, 2.5, 1.9                    4.4, 5.7, 4.3                                                 2.1, 2.4, 1.6                                                                                                
      Vaccine                                                                                                                          2.5, 2.9, 2.2                    5.6, 6.5, 5.5                                                 2.0, 2.5, 1.0                                                                                                
      Placebo                                                                                                                          1.9, 2.1, 1.7                    3.2, 4.8, 3.0                                                 2.3, 2.3, 2.2                                                                                                
  **Annual loss to follow-up incidence (%): total, pre-unblinding, post-unblinding**                                                   10.2, 8.0, 12.2                  8.2, 8.1, 8.3                                                 10.8, 11.4, 9.7                                                                                              
      Vaccine                                                                                                                          10.0, 7.8, 11.9                  7.8, 8.1, 7.8                                                 9.8, 10.5, 8.4                                                                                               
      Placebo                                                                                                                          10.4, 8.2, 12.5                  8.6, 8.0, 8.7                                                 11.9, 12.3, 11.1                                                                                             

The pooled MITT cohort included 6266 participants (n = 3129 vaccine; n = 3137 placebo) from the three Phase 2b studies and 826 participants (n = 449 vaccine; n = 377 placebo) from the three Phase 1--2 studies. In the MITT cohort, 76.2% and 54.7% of the Phase 2b and Phase 1--2 study participants were men, respectively. Within each sex, baseline characteristics were balanced between the vaccine and placebo arms (Table B in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

The pooled Ad5 cohort included 5824 participants (n = 2900 vaccine; n = 2924 placebo) from the three Phase 2b studies and 747 participants (n = 402 vaccine; n = 345 placebo) from the three Phase 1--2 studies, with balanced baseline characteristic between the vaccine and placebo arms. For simplicity, we report the remaining meta-analysis results excluding the Phase 1--2 studies, since over 91% of the HIV-1 infections occurred in the Phase 2b studies and both the overall and subgroup HR estimates were very similar when the Phase 1--2 studies were included (Fig C in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

Overall vaccine effect in Step, Phambili, and HVTN505 {#sec012}
-----------------------------------------------------

The covariate-unadjusted cumulative incidences of HIV-1 infection in the MITT and Ad5 cohorts based on the phase 2b studies are plotted in [Fig 3A and 3B](#pone.0136626.g003){ref-type="fig"}. In the MITT cohort, 403 (n = 224 vaccine; n = 179 placebo) of 6266 participants acquired HIV-1, with a non-significantly higher incidence in vaccine recipients (HR 1.21, 95% CI 0.99--1.48, *P* = 0.06). In the Ad5 cohort, 372 (n = 205 vaccine; n = 167 placebo) of 5824 participants acquired HIV-1 (HR 1.19, 95% CI 0.97--1.47, *P* = 0.09). The overall interaction tests indicated that the HRs significantly differed between the three phase 2b studies in the MITT and Ad5 cohorts (*P* = 0.05 and 0.01, respectively), possibly due to the difference between the two vaccine regimens. Despite the limited power to detect HR differences (Fig D in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}), interaction tests indicated that the HRs significantly differed by vaccine regimen in each of the MITT and Ad5 cohorts (*P* = 0.03 and 0.008, respectively ([Fig 4A and 4B](#pone.0136626.g004){ref-type="fig"}). Specifically, when we analyzed each vaccine regimen, the estimated HR for DNA/rAd5 in HVTN505 was 0.88 (95% CI 0.61--1.26, *P* = 0.48) in the MITT cohort and 0.73 (95% CI 0.47--1.12, *P* = 0.15) in the Ad5 cohort compared to 1.41 (95% CI 1.11--1.78, *P* = 0.005) in both cohorts for MRKAd5 in Step and Phambili combined, suggesting differences in the effect of the two vaccine regimens or in the study populations.

![Kaplan-Meier Curves and Their Difference (Vaccine vs Placebo) of Cumulative Incidence of HIV-1 Infection.\
**These incidence estimates were not adjusted for covariates.** Panel A is for the MITT cohort and Panel B is for the Ad5 cohort based on Step, Phambili and HVTN505 combined using all follow-up time; Panel C is for the Ad5 Cohort based on HVTN505 alone using follow-up time before unblinding, and Panel D is based on Step and Phambili combined using follow-up time before unblinding. The MITT cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received at least one dose of vaccine or placebo; the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo.](pone.0136626.g003){#pone.0136626.g003}

![Estimated Covariate-Adjusted HRs of HIV-1 Infection (Vaccine vs Placebo) Based on Step, Phambili and HVTN505 Combined.\
Panel A is for the MITT Cohort, Panel B is for the Ad5 cohort, and Panel C is for circumcised Ad5-negative men in the Ad5 Cohort. The MITT cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received at least one dose of vaccine or placebo; the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Red lines are 95% confidence intervals indicating HRs significantly different from 1.0; blue lines are 95% confidence intervals indicating HRs not significantly different from 1.0. Shaded rows indicate significantly different HRs within subgroups.](pone.0136626.g004){#pone.0136626.g004}

In studying the overall HR in different time periods pooling over the three efficacy trials, the overall HRs were almost identical by period of follow up (FU≤18 months vs. FU\> 18 months) (interaction *P* \> 0.90) ([Fig 4](#pone.0136626.g004){ref-type="fig"}), and the estimated HR over time in daily increments was fairly constant throughout follow-up (Fig E in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). An additional analysis showed similar HRs across subgroups who received one, two, or three rAd5-HIV vaccinations (Table C in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

Step and Phambili pooled {#sec013}
------------------------

Additional analyses concerning the issue of unblinding and subgroups were then conducted in Step and Phambili combined. HVTN505 was excluded based on several considerations. First, Step and Phambili tested the same MRKAd5 vaccine whereas HVTN505 tested a different vaccine. Second, the HRs differed significantly between the two vaccine regimens as shown above. Third, Step and Phambili comprised about 70% of the total HIV-1 infections and about 90% of the infections diagnosed after 18 months of follow-up. Lastly, Step and Phambili included Ad5-positive participants, uncircumcised men, and women, groups that were ineligible for HVTN505.

When restricting the analysis of Step and Phambili to follow-up time before unblinding where balance in HIV-1 risk factors between the vaccine and placebo groups is most assured, 114 (n = 65 vaccine; n = 49 placebo) of 3770 MITT participants acquired HIV-1, with a non-significantly higher incidence in MRKAd5 vaccine recipients (HR 1.30, 95% CI 0.89--1.14, P = 0.18) (Figs [3D](#pone.0136626.g003){ref-type="fig"} and [5](#pone.0136626.g005){ref-type="fig"}). Additional sensitivity analyses explored the impact of potential bias in the post-unblinding period (Methods, Table D and Fig F in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

![Estimated HRs in the MITT Cohort (Panel A) and Ad5 Cohort (Panel B) Using Follow-up Time before Unblinding Based on Step, Phambili and HVTN505.\
The MITT cohort included all randomly assigned participants HIV uninfected at study entry, who received at least one dose of vaccine or placebo; the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Blue lines are 95% confidence intervals indicating HRs not significantly different from 1.0.](pone.0136626.g005){#pone.0136626.g005}

Comparing Step and Phambili, there was no strong evidence of a differential vaccine effect when including all follow-up, restricting to FU≤18 months, or restricting to FU\> 18 months (Fig G in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). Similar HRs were also observed among subgroups defined by sex, baseline Ad5 serostatus or baseline circumcision status when evaluated over the entire duration of follow-up (all interaction *P*\>0.30) (Fig H(A) in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). Of note, when restricting the analysis to circumcised and Ad5-seronegative men, the study population participating in HVTN505, the estimated HR was 0.97 (95% CI 0.58--1.63, *P* = 0.91) in Step and Phambili combined (Fig C and Fig I in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}), supporting that neither vaccine regimen increased HIV-1 risk in this subgroup.

We next analyzed the vaccine effect by follow-up time within each participant subgroup (Figs H, J, and K in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}). Statistical tests of interaction suggested a differential vaccine effect by duration of follow-up and baseline circumcision status (3-way interaction *P* = 0.002). Uncircumcised men had a vaccine-increased risk of HIV-1 infection before 18 months of enrollment (HR 2.90, 95% CI 1.49--5.65, *P* = 0.002), whereas circumcised men had a vaccine-increased risk after 18 months (HR 2.08, 95% CI 1.17--3.68, *P* = 0.01). Similarly, the vaccine-increased risk varied by duration of follow-up and baseline Ad5 serostatus (3-way interaction *P* = 0.004). Ad5-negative participants had a significant vaccine-increased risk only after 18 months (HR 1.92, 95% CI 1.07--3.46, *P* = 0.03); the HRs for this group differed significantly before and after 18 months (interaction *P* = 0.01). Ad5-positive participants had an early increased risk (HR 1.92, 95% CI 1.25--2.93, *P* = 0.003); however, the HRs for these participants did not significantly differ by follow-up time period. Of the 24 interaction tests conducted, one had an FWER-adjusted p-value \< 0.05 and 11 had FDR-adjusted q-values \< 0.20, supporting that several of the differential vaccine effect results are likely to be real ([Table 3](#pone.0136626.t003){ref-type="table"}).

10.1371/journal.pone.0136626.t003

###### Unadjusted and Multiplicity-Adjusted P-values from Interaction Tests of Differential Vaccine Effect by Follow-up Time Period and Subgroup Based on Step and Phambili.

Holm-Bonferroni family-wise-error-rate (FWER)-adjusted p-values and false-discovery-rate (FDR)-adjusted q-values are reported in the last two columns.

![](pone.0136626.t003){#pone.0136626.t003g}

  Follow-up Time Period                          Factor (Subgroup)          Unadjusted Interaction P-values   FWER-adjusted P-values   FDR-adjusted Q-values
  ---------------------------------------------- -------------------------- --------------------------------- ------------------------ -----------------------
  Overall                                        Study (Step vs Phambili)   0.21                              1.0                      0.37
  Gender (Male vs Female)                        0.62                       1.0                               0.79                     
  Ad5 serostatus (positive vs negative)          0.24                       1.0                               0.39                     
  Ad5 serostatus in men (positive vs negative)   0.37                       1.0                               0.55                     
  Circumcision status (yes vs no)                0.54                       1.0                               0.77                     
  FU ≤ 18 months                                 Study (Step vs Phambili)   0.92                              1.0                      0.96
  Gender (Male vs Female)                        0.84                       1.0                               0.92                     
  Ad5 serostatus (positive vs negative)          0.004                      0.09                              0.03                     
  Ad5 serostatus in men (positive vs negative)   0.002                      0.05                              0.03                     
  Circumcision status (yes vs no)                0.01                       0.21                              0.05                     
  FU \> 18 months                                Study (Step vs Phambili)   0.06                              0.96                     0.15
  Gender (Male vs Female)                        0.61                       1.0                               0.79                     
  Ad5 serostatus (positive vs negative)          0.21                       1.0                               0.37                     
  Ad5 serostatus in men (positive vs negative)   0.05                       0.83                              0.13                     
  Circumcision status (yes vs no)                0.08                       1.0                               0.18                     
  FU ≤ 18 months vs FU \> 18 months              All participants           0.70                              1.0                      0.80
  Female                                         0.96                       1.0                               0.96                     
  Male                                           0.68                       1.0                               0.80                     
  Ad5-negative                                   0.01                       0.21                              0.05                     
  Ad5-positive                                   0.16                       1.0                               0.32                     
  Ad5-negative men                               0.003                      0.07                              0.03                     
  Ad5-positive men                               0.05                       0.83                              0.13                     
  Circumcised men                                0.02                       0.40                              0.08                     
  Uncircumcised men                              0.04                       0.77                              0.13                     

Discussion {#sec014}
==========

This meta-analysis of six randomized, double-blind, placebo-controlled clinical studies and their long-term follow-up in 7092 participants is the first of its kind to systematically evaluate the effect of rAd5-vectored HIV-1 vaccines on susceptibility to HIV-1 acquisition. Based on rigorous statistical analysis of pooled individual participant-level data, we did not observe statistically significant evidence of increased risk of HIV-1 infection among vaccine recipients when all study participants and follow-up time were considered. We observed that vaccine-associated risk of HIV-1 infection significantly differed by vaccine regimen and/or study population: there was evidence of increased risk for Step and Phambili that tested the MRKAd5 vaccine in both men and women, but no evidence of vaccine-increased risk when the VRC-DNA/rAd5 vaccine was analyzed by itself (using data from circumcised Ad5-negative men in HVTN505, and men and women in the Triad studies). When restricting to follow-up while the studies were blinded, the evidence for increased risk was not statistically significant for all studies combined or separately for either vaccine regimen. When subgroups were examined separately over early and late follow-up, nominally statistically significant evidence was observed for early increased risk among uncircumcised men, Ad5-positive participants and Ad5-positive men, and for late increased-risk among circumcised men, Ad5-negative participants and Ad5-negative men.

By aggregating data, meta-analysis provides statistical power to discover signals that individual studies were under-powered to assess. Our meta-analysis demonstrated a significantly increased risk of HIV-1 acquisition among MRKAd5 vaccine recipients who entered the trials with evidence of past Ad5 infection; this effect appeared not to mitigate after long term follow-up. In addition, among MRKAd5 vaccine recipients without evidence of past Ad5 infection or who were circumcised men, significantly higher risk was seen during long term follow-up. These observations were not previously reported in the individual studies. It is uncertain whether these observations were confounded by potential imbalances in HIV exposure between the vaccine and placebo groups in the late time period due to unblinding, although the likelihood of such confounding reversing the inference of increased risk appeared to be low based on our sensitivity analyses. Previous studies in Step participants showed that pre-existing Ad immunity could affect the magnitude and nature of vaccine-induced immune responses \[[@pone.0136626.ref029], [@pone.0136626.ref030]\]. However, whether Ad-specific or other vaccine-induced immune responses are related to differences in risk of HIV-1 acquisition after vaccination is unclear.

By aggregating data, meta-analysis also enables answering questions across study products and/or study populations that cannot be feasibly addressed with individual studies. Our meta-analysis showed that vaccine-associated risk of HIV-1 infection differed significantly between the MRKAd5 and DNA/rAd5 vaccine regimens when including all study participants and all follow-up time. When restricting to circumcised Ad5-negative men, the study population that provided the majority of infection data for DNA/rAd5, the vaccine effect on HIV-1 infection did not seem to differ between the two vaccine regimens, and there was no evidence of increased risk for either regimen. When restricting to follow-up while the studies were blinded, the vaccine effect did not seem to differ, either. Although the lack of evidence in both subgroups could be due to the limited statistical power to detect vaccine effect differences with a smaller number of infections, the latter analyses circumvented the issue of potential post-unblinding confounding by measured or unmeasured factors associated with HIV-1 infection risk. These findings suggest that differences in HIV antigen designs could have played a role in the different vaccine effects of MARKAd5 and DNA/rAd5; however, it is prudent to address such a hypothesis in the appropriate study populations and/or follow-up timeframe.

Because none of the trials used an empty rAd5 vector as a control arm, this meta-analysis cannot parse out if the vaccine-associated increased risk was due to the rAd5 vector or the HIV-1 vaccine inserts. A non-human primate challenge trial of a rAd5-vectored SIV vaccine mimicking the MRKAd5 vaccine addressed the vector versus insert question by using a control group of empty rAd5 vector immunized animals \[[@pone.0136626.ref031]\]. Although this trial recapitulated the result in Step of vaccine-increased risk, implicating the SIV vaccine inserts as the cause, it is unclear whether this result would apply to HIV-1 vaccines. We hypothesize that the HIV antigen design and the HIV-specific immune response patterns are more likely to influence susceptibility to HIV than the transient and non-specific immune stimulation of a vaccine vector.

This meta-analysis has several limitations. First, the selected trials tested two different rAd5-vectored vaccine regimens with different biological properties in different geographic regions and study populations. Therefore, the ability to interpret the results assumes that it is meaningful to combine data across the multiple interventions and settings that were included. Second, this study, like most meta-analyses, was not prospectively planned. Therefore, findings from this study should not be regarded as additional evidence from independent experiments, but rather integrated information across existing studies. Third, this study provided limited power for tests of different vaccine effects due to small numbers of infections in some subgroups, limited long-term follow-up prior to unblinding, and limited long-term follow-up in HVTN505. Fourth, unblinding of trial participants may have introduced bias in the analysis. Differential dropout, risk behavior and/or ascertainment of HIV-1 infection between treatment groups could have occurred after unblinding. To reduce such bias, all analyses controlled for baseline measured factors potentially prognostic for HIV-1 whose distributions could differ between treatment groups after unblinding. Future analysis may be conducted to provide causal vaccine effect estimates adjusting for prognostic factors (e.g. risk behavior) over time. The sensitivity analyses presented in the Supplement quantify the degree of such bias due to both measured and unmeasured confounding that could lead to reversing a conclusion of vaccine-increased risk. Lastly, early stopping of HVTN505 may cause the estimate of overall vaccine effect to be biased, although a bias-corrected analysis of HVTN505 showed only a small influence of early stopping (Methods and Fig L in [S1 Supporting Information](#pone.0136626.s001){ref-type="supplementary-material"}).

This study provides evidence for increased risk associated with the MRKAd5 vaccine overall and in subgroups except the circumcised and Ad5-negative men. While this meta-analysis does not provide a reliable basis for predicting whether rAd5-vectored vaccines for other pathogens or other rAd-vectored vaccines for HIV-1 would increase susceptibility to infection in HIV-1 at-risk populations, for large efficacy trials of such vaccines it provides a rationale for adding monitoring plans enabling detection of such increased susceptibility. Further research is needed to understand which attributes of the MRKAd5 vaccine regimen should be avoided in future HIV-1 vaccine design.
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